Histamine-1 Receptor Antagonist Drug Class List

Drugs in Drug Class: Histamine-1 Receptor Antagonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kenvue Brands	ZYRTEC-D 12 HOUR	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021150-002	Nov 9, 2007		OTC	Yes	Yes
Kenvue Brands	ZYRTEC HIVES	cetirizine hydrochloride	TABLET;ORAL	019835-005	Nov 16, 2007		DISCN	Yes	No
Kenvue Brands	ZYRTEC HIVES	cetirizine hydrochloride	TABLET;ORAL	019835-006	Nov 16, 2007		DISCN	Yes	No
Kenvue Brands	ZYRTEC ALLERGY	cetirizine hydrochloride	TABLET;ORAL	019835-003	Nov 16, 2007		OTC	Yes	No

Histamine-1 Receptor Antagonist Market Analysis and Financial Projection

Last updated: April 24, 2026

Market Dynamics and Patent Landscape for Histamine-1 Receptor Antagonists (H1 Antagonists)

H1 receptor antagonists span multiple therapeutic sub-markets: over-the-counter allergy/urticaria symptom relief, prescription treatment of chronic allergic conditions, and sedating versus non-sedating antihistamines. Patent activity is concentrated in new molecular entities in the “next-generation” antihistamine space, extended-release and formulation IP, and line extensions that pair H1 blockade with additional actives. Most first-wave H1 antagonists are long off-patent, which drives a market structure dominated by generics, switching among brands, and value capture through formulation and dosing convenience.

What is the commercial structure of the H1 antagonist market?

Demand drivers

• Seasonal allergic rhinitis and chronic spontaneous urticaria (CSU) drive recurring symptom-relief use.
• Sedation liability and next-day impairment concerns steer patient and prescriber preference toward non-sedating agents in many settings.
• Formulation convenience (once-daily dosing, melt/tablet formats, pediatric ease of use) materially affects retail and formulary share.

Supply and competitive dynamics

• Generics dominate the core first-line symptom relief class because older H1 antagonists have long expired patents and widespread manufacturing.
• Brand differentiation clusters around:
  • Non-sedating profiles and reduced anticholinergic burden
  • Controlled-release or optimized absorption for once-daily adherence
  • Pediatric and special-dosing formulations (liquid, ODT)
  • Combinations when clinically used (with other allergy or respiratory agents)

Implication for R&D and licensing

• New chemical entities (NCEs) face tight patent runway because H1 receptor antagonism as a mechanism is well-established.
• Viable patent portfolios typically require at least one of:
  • A new chemical scaffold with strong novelty and measurable clinical differentiation
  • Formulation IP with meaningful constraints (release kinetics, particle/solid-state, dosing regimen)
  • Additional therapeutic components paired with H1 antagonism that create new claims

---

How do patent lifecycles shape H1 antagonist portfolios?

Typical life-cycle pattern in this class

• Early molecules (first and second-generation antihistamines) reached peak adoption in different decades and are now generic.
• Recent patenting has shifted to:
  • New molecular entities with improved selectivity or tolerability
  • Optimized pharmacokinetics and dosing regimens
  • Patent estates built around polymorphs, solvates, and controlled release

Key patent barriers

• Low novelty risk for “just another H1 antagonist” reduces the probability of broad exclusion.
• If the formulation and solid-state features are not tightly tied to stability, bioavailability, and clinical performance, enforcement leverage weakens.
• Regulatory reliance on existing antihistamine endpoints can compress differentiation claims, making litigation outcomes more dependent on chemistry and formulation details than on broad pharmacology.

---

Which H1 antagonists anchor the patent and commercial landscape?

Core non-sedating and sedating anchors (market relevance)

Below are widely used H1 antagonists that anchor market demand. Many are generic, which shifts “value of IP” toward remaining patents on newer formulations or newer molecules.

Drug (generic)	Typical positioning	Patent posture in the class (directional)	Market role
Fexofenadine	Non-sedating	Largely generic globally	Allergy symptom relief core
Loratadine	Non-sedating	Largely generic	Allergic rhinitis, urticaria
Cetirizine	Mildly sedating for some	Largely generic	Allergic rhinitis, CSU
Levocetirizine	Non-sedating relative	Largely generic	Rhinitis, urticaria
Desloratadine	Non-sedating	Largely generic	Rhinitis, CSU
Bilastine	Non-sedating	Mix of generics and residuals depending on jurisdiction	EU-origin growth
Azelastine	Intranasal H1	Often formulation/form factor driven	Local allergic rhinitis
Dimenhydrinate, diphenhydramine	Sedating/older	Off-patent	Short-term symptomatic and motion sickness uses

How this affects the patent landscape

• With older oral H1 antagonists largely generic, patent value concentrates in:
  • Remaining jurisdictions where certain forms still have protection
  • Intranasal and niche delivery formats
  • New entrants with differentiated pharmacology or solid-state/formulation estates

Regulatory framework that influences exclusivity strategy

• The FDA’s Orange Book lists drug products and associated patent and exclusivity information for approved drugs; for reformulations and line extensions, staying power often depends on what patents are listed for specific products and strengths. (FDA Orange Book: [1])

---

Where is remaining patent activity most likely in H1 antagonists?

1) Next-generation molecular entities

Patent value persists when a new molecule:

• Has demonstrable clinical differentiation at labeled endpoints
• Avoids obviousness pitfalls by distinct scaffold, selectivity profile, or binding mode
• Generates patentable claims around stereochemistry and specific forms, not only the active substance

This is the area with fewer products, but the highest upside for defensible exclusivity.

2) Formulation and solid-state IP

In H1 antagonist development, formulation IP commonly includes:

• Controlled release / extended release
• Particle size engineering for absorption profiles
• Polymorphs/solvates/hydrates with stability and bioavailability linkage
• Taste-masking and dose-form constraints for pediatric use (ODT, liquid)

Formulation estates are often enforceable at product level when patents are properly tied to marketed strengths and dosage forms.

3) Combination products

When H1 blockade is paired with another therapeutic mechanism, IP can expand beyond the H1 compound itself:

• New fixed-dose combinations can claim a regimen that is not covered by older monotherapy patents.
• The patent strategy then depends on whether the combination’s claims survive obviousness and whether both components have sufficient non-infringing coverage.

4) New routes and local delivery

Intranasal delivery for allergic rhinitis is a repeat site of line extensions because:

• Patentable compositions and device-related dosing regimens can persist longer than oral generics
• Local pharmacokinetics can shift the clinical positioning of an established active

---

What does the evidence base say about H1 antagonist efficacy and the practical endpoints that patents must clear?

H1 antagonists are classically used for:

• Allergic rhinitis symptom relief
• CSU symptom control
• Acute allergic symptoms and histamine-driven pruritus/urticaria

This clinical routine standardizes the market endpoints developers use. The patent landscape then depends on whether differentiation is demonstrated on:

• Symptom score reduction
• Time to onset and duration
• Tolerability and sedation impact (especially for driving impairment and occupational use)

Clinical guidance in major references reinforces that multiple antihistamines can treat similar histamine-driven conditions, which makes “mechanism” alone insufficient to differentiate in patent litigation. (NICE guideline on urticaria: [2]; ARIA guideline: [3])

---

How does the enforcement environment shape strategy for H1 antagonist patents?

Litigation and enforcement focus

Because many oral H1 antagonists are off-patent, enforcement risk and opportunity concentrate in:

• Product-specific patents listed in regulatory registries
• Solid-state and formulation patents that tie to commercial manufacturing and marketed dosage forms
• Jurisdiction-specific exclusivity and listing practices (important because generic entry can be product-by-product)

Regulatory listing as a leverage point

• FDA Orange Book patent listing determines what is asserted in ANDA paragraph IV challenges in the US. (FDA Orange Book: [1])
• Internationally, the patent term and listing mechanics vary, but the commercial mechanism remains similar: the branded product’s patent estate must match the generic product’s intended strength and dosage form to create actionable infringement exposure.

---

Where are the highest-value white spaces for new entrants?

A) Differentiated delivery with enforceable composition claims

• Local delivery formats (intranasal) and patient-friendly oral dose forms are white spaces because manufacturing steps and excipient systems can support claims.
• The value is highest when the delivery improvement translates into clearly labeled clinical claims that the brand can market and support.

B) Stereochemistry or scaffold novelty with differentiated tolerability

• A next-generation antihistamine with clear non-sedating performance and a distinct chemistry platform can sustain longer exclusivity value than a simple line extension.

C) Durable pediatric and adherence-driven formulations

• Pediatric indication expansions and dosing convenience can support market durability even when active substance patents expire, if formulation IP remains enforceable.

---

What is the practical patent-to-market timing for H1 antagonists?

Typical timeline effects

• For older H1 antagonists, patent expiration has largely already occurred, pushing the market into generics and parallel trade.
• New entrants need to time:
  • Filing strategies (earliest priority and continuation depth)
  • Clinical development (to avoid narrow filing windows)
  • Regulatory approval so that exclusivity aligns with the patent term and listing mechanics

Because H1 antagonists share common clinical endpoints, the differentiation required to justify prosecution of broad claims depends heavily on:

• Demonstrated pharmacology and clinical effect
• Solid-state and formulation proof that ties performance to specific protected features

---

Key competitor dynamics: how brands keep share after primary patent expiry

The H1 antagonist market is structurally resistant to sustained premium pricing because:

• Retail and payer formularies readily substitute equivalent antihistamines.
• Sedation differences can be overridden by patient-specific factors and local guideline adoption.

Therefore, branded companies preserve share through:

• Extended-release and dosing convenience upgrades
• Differentiated formulations that reduce sedation risk or improve compliance
• Product-level renewals where formulation patents remain enforceable

---

Key Takeaways

• The H1 antagonist market is generics-led for older oral antihistamines; patent value is concentrated in remaining jurisdictional pockets, formulation/solid-state estates, new delivery routes, and select next-generation molecular entities.
• Patent strategy must connect claims to product-specific deliverables (release profile, solid-state form, dosage regimen) because clinical endpoints across antihistamines converge.
• The highest upside for new entrants is enforceable IP paired with demonstrable tolerability or pharmacokinetic differentiation, not mechanism-only novelty.
• FDA Orange Book patent listing mechanics drive US generic entry leverage; product-level patents are the key enforcement unit. (FDA Orange Book: [1])

---

FAQs

1) Are most first-generation and many second-generation H1 antihistamines still protected by patents?

No; much of the class is off-patent, which leaves the market to generics and substitution dynamics. Patent value is now more concentrated in formulations, local routes, and newer molecules.

2) What patent types matter most for H1 antagonist line extensions?

Formulation patents (including controlled release) and solid-state patents (polymorph/solvate and manufacturing-specific features) matter most because they map to product-specific dosage forms and strengths.

3) How do payer and guideline preferences affect patent value in this class?

Guidelines standardize symptom relief use across antihistamines and reduce differentiation based on mechanism alone, shifting value toward tolerability and delivery-driven differentiation.

4) What role does the FDA Orange Book play in enforcement for H1 antagonists?

It is the key US registry that lists patents associated with specific FDA-approved drug products, which then governs how ANDA challenges connect to listed claims. (FDA Orange Book: [1])

5) Where should an R&D portfolio look if the goal is defensible exclusivity?

Look for clinically meaningful tolerability and pharmacokinetic differentiation plus enforceable, product-linked formulation or solid-state IP, or new local delivery platforms with composition and dosing regimen claims.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA / Orange Book. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-04-24)

[2] National Institute for Health and Care Excellence. (2013; updated). Urticaria: assessment and management (NICE guideline). https://www.nice.org.uk/guidance (accessed 2026-04-24)

[3] National Institute for Health and Care Excellence. (2016; updated). Allergic rhinitis (ARIA) based guidance and related recommendations. https://www.nice.org.uk/guidance (accessed 2026-04-24)